Sigyn Therapeutics (SIGY) Non-Current Debt (2017 - 2025)
Sigyn Therapeutics' (SIGY) quarterly Non-Current Debt came in at $2.5 million in Q3 2025, up 32.66% quarter-over-quarter from $1.9 million in Q4 2024.
Powered by 
Analysis
Sigyn Therapeutics (SIGY) Non-Current Debt (2017 - 2025) Analysis & Trends
Sigyn Therapeutics has disclosed Non-Current Debt across 4 years of filings, most recently posting $2.5 million for Q3 2025.
- In Q3 2025, Non-Current Debt changed N/A year-over-year to $2.5 million; the TTM figure through Sep 2025 stood at $2.5 million (changed N/A YoY), while the FY2024 annual figure was $1.9 million, changed N/A from the prior year.
- Non-Current Debt came in at $2.5 million for Q3 2025 at Sigyn Therapeutics, up from $1.9 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $2.5 million in Q3 2025 to a low of $1.9 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.19 Bn | 175.58 Bn | 7.27 Bn | 29.60 Bn |
| 2 | Intuitive Surgical | 127.77 Bn | 122.55 Bn | 1.96 Bn | - |
| 3 | Medtronic | 117.13 Bn | 108.31 Bn | 6.34 Bn | 25.62 Bn |
| 4 | Stryker | 104.67 Bn | 101.20 Bn | 4.50 Bn | 14.19 Bn |
| 5 | Boston Scientific | 64.48 Bn | 63.94 Bn | 3.85 Bn | 10.92 Bn |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | 598.70 Mn |
| 7 | Alcon | 33.06 Bn | 31.61 Bn | 1.68 Bn | -1.00 Mn |
| 8 | Dexcom | 32.37 Bn | 30.43 Bn | 830.00 Mn | - |
| 9 | Steris | 20.76 Bn | 20.28 Bn | 684.20 Mn | 1.65 Bn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | 2.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | 2.51 Mn |
| Dec 31, 2024 | 1.89 Mn |
| Sep 30, 2019 | 40,010.00 |
| Dec 31, 2017 | 18,880.00 |
| Jun 30, 2017 | 17,505.00 |